THE LONG-TERM OUTCOME OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET FAILING ABVD MIGHT BE WORSE THAN THAT OF INTERIM PET POSITIVE PATIENTS UNDERGOING EARLY TREATMENT INTENSIFICATION WITH ESCALATED BEACOPP

被引：0
|
作者：
Zaucha, J. M. [1 ,2 ]
Malkowski, B. [3 ]
Subocz, E. [4 ]
Tajer, J. [5 ]
Kulikowski, W. [6 ]
Panebianco, M. [7 ]
Grad, J. [8 ]
Rybka, J. [9 ]
Kroll-Balcerzak, R. [10 ]
Romanowicz, A. [11 ]
Chamier-Cieminska, A. [12 ]
Kurczab, P. [13 ,14 ]
Cimino, G. [7 ]
Chauvie, S. [15 ]
Knopinska-Posluszny, W. [6 ]
Walewski, J. [5 ]
Gallamini, A. [16 ]
机构：
[1] Gdynia Oncol Ctr, Gdynia, Poland
[2] Med Univ Gdansk, Dept Oncol Propedeut, Gdansk, Poland
[3] Oncol Ctr, Dept Nucl Med, Bydgoszcz, Poland
[4] Mil Inst Med, Dept Hematol, Warsaw, Poland
[5] Maria Sklodowska Curie Mem Inst Oncol, Dept Lymphoproliferat Dis, Warsaw, Poland
[6] Warmia & Mazury Med Univ, Interior Minist Hosp, Clin Dept Hematol, Olsztyn, Poland
[7] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
[8] Reg Hosp, Hematol Unit, Opole, Poland
[9] Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transp, Wroclaw, Poland
[10] Univ Med Sch, Dept Hematol, Poznan, Poland
[11] Cent Clin Hosp MSW, Dept Hematol, Warsaw, Poland
[12] Oncol Ctr, Dept Clin Oncol, Bydgoszcz, Poland
[13] Med Ctr Mrukmed, Outpatient Chemotherapy Unit, Rzeszow, Poland
[14] Subcarpathian Oncol Ctr, Dept Clin Oncol, Brzozow, Poland
[15] Santa Croce & Carle Hosp, Med Phys Dept, Cuneo, Italy
[16] Univ Nice, Lacassagne Canc Ctr, Res Innovat & Stat Dept, Nice, France
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P100
引用
收藏
页码：53 / 54
页数：2
相关论文
共 49 条
  • [21] EARLY INTERIM FDG-PET IN ADVANCED-STAGE HODGKIN LYMPHOMA (HL). LONG-TERM RESULTS OF THE ITALIAN-DANISH COOPERATIVE STUDY
    Gallamini, A.
    Hutchings, M.
    Rigacci, L.
    Specht, L.
    Merli, F.
    Hansen, M.
    Patti, C.
    Loft, A.
    Di Raimondo, F.
    D'Amore, F.
    Biggi, A.
    Pregno, P.
    Stelitano, C.
    Sancetta, R.
    Trentin, L.
    Luminari, S.
    Iannitto, E.
    Viviani, S.
    Pierri, I.
    Torchio, P.
    Levis, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 191 - 191
  • [22] Role of Interim PET-CT Scan on Long Term Follow Up of Patients With Hodgkin Lymphoma: A Single-Center Study in a Developing Country
    Azeez, Saya
    Al-Mashhadani, Ahmad
    Sadiq, Nasherwan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S344 - S344
  • [23] Interim FDG PET/CT Predicts Response to Treatment and Outcome in Hodgkin's Lymphoma Patients; Experience from KHCC Tertiary Cancer Center in Jordan
    Al-Ibraheem, A.
    Anwer, F. M.
    Shagera, Q.
    Juweid, M.
    Khalaf, A. N.
    Ma'koseh, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S355 - S356
  • [24] Superior Long-Term Outcome of Patients With Early Transformation of Non-Hodgkin Lymphoma Undergoing Stem Cell Transplantation
    Reddy, Nishitha
    Oluwole, Olalekan
    Greer, John P.
    Goodman, Stacey
    Engelhardt, Brian
    Jagasia, Madan H.
    Savani, Bipin N.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (06): : 406 - 411
  • [25] Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial
    Linton, Kim M.
    Oladipo, Joanna M.
    Counsell, Nicholas
    Taylor, Janet
    Burton, Cathy
    Oakley, Rachel
    Williams, Joanna
    Barrington, Sally F.
    Byers, Richard
    Illidge, Timothy
    Radford, John A.
    BLOOD, 2020, 136
  • [26] Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 129 - 131
  • [27] Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens
    Parsons, Susan K.
    Yu, Kristina S.
    Liu, Nicholas
    Kumar, Supriya
    Fanale, Michelle A.
    Holmes, Katie
    Flores, Carlos
    Surinach, Andy
    Flora, Darcy R.
    Evens, Andrew M.
    BLOOD, 2021, 138
  • [28] Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
    Robert Seifert
    David Kersting
    Christoph Rischpler
    Patrick Sandach
    Justin Ferdinandus
    Wolfgang P. Fendler
    Kambiz Rahbar
    Matthias Weckesser
    Lale Umutlu
    Christine Hanoun
    Andreas Hüttmann
    Hans Christian Reinhardt
    Bastian von Tresckow
    Ken Herrmann
    Ulrich Dührsen
    Michael Schäfers
    Leukemia, 2022, 36 : 2845 - 2852
  • [29] Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
    Seifert, Robert
    Kersting, David
    Rischpler, Christoph
    Sandach, Patrick
    Ferdinandus, Justin
    Fendler, Wolfgang P.
    Rahbar, Kambiz
    Weckesser, Matthias
    Umutlu, Lale
    Hanoun, Christine
    Huettmann, Andreas
    Reinhardt, Hans Christian
    von Tresckow, Bastian
    Herrmann, Ken
    Duehrsen, Ulrich
    Schaefers, Michael
    LEUKEMIA, 2022, 36 (12) : 2845 - 2852
  • [30] OUTCOME AND PROGNOSTIC FACTORS IN PATIENTS WITH HODGKIN LYMPHOMA (HL) WHO REMAIN PET/CT-POSITIVE AFTER ABVD COMBINATION CHEMOTHERAPY: POTENTIAL APPLICATIONS FOR THE DESIGN OF SUBSEQUENT TREATMENT
    Vassilakopoulos, T.
    Rontogianni, P.
    Pangalis, G.
    Boutsikas, G.
    Prassopoulos, V.
    Masouridis, S.
    Kokoris, S.
    Dimou, M.
    Galani, Z.
    Chatziioannou, S.
    Moschogiannis, M.
    Sachanas, S.
    Yiakoumis, X.
    Pappi, V.
    Sinni, E.
    Tzenou, T.
    Petevi, K.
    Kanellopoulos, A.
    Ntalagiorgos, T.
    Vardounioti, I.
    Koutsi, K.
    Papageorgiou, L.
    Pessach, E.
    Telonis, V.
    Variamis, E.
    Kyrtsonis, M. C.
    Dimopoulou, M.
    Siakantaris, M.
    Beris, P.
    Datseris, I.
    Panayiotidis, P.
    Meletis, I.
    Angelopoulou, M.
    HAEMATOLOGICA, 2012, 97 : 562 - 562
12345